Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week safety study of once-daily fluticasone furoate/vilanterol versus fluticasone propionate in adolescents and adults with asthma
2009-012054-20Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone, vilanterol and fluticasone propionate in asthma (3 arms), sponsored by GSK. Primary endpoints: Overall safety and tolerability over 12 months and Relative safety versus fluticasone propionate. Started Aug 2009; status: completed.
02
Drugs
fluticasonevilanterolfluticasone propionate
03
Conditions
asthma
Beyond the preview
Go deeper on 2009-012054-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012054-20.